Richa Rathore
A new study from Washington University School of Medicine in St. Louis suggests that a two-drug combination targeting a tumor’s energy sources could be as effective and less toxic than methotrexate, a long-used chemotherapy drug often given in high doses to treat osteosarcoma, a bone cancer. Shown is a cross section of osteosarcoma.
An innovative approach to treating bone tumors – starving cancer cells of the energy they need to grow – could one day provide an alternative to a commonly used chemotherapy drug without the risk of severe side effects, suggests a new study from Washington University School of Medicine in St. Louis. Studying human cancer cells and mice, the researchers said that a two-drug combination targeting a tumor’s energy sources could be as effective and less toxic than methotrexate, a long-used chemotherapy drug often given in high doses to treat osteosarcoma, a bone cancer.
HMP Global Announces Launch of Virtual Conference, Dermatology Week
Share Article
Multi-day online program led by trailblazing faculty will be dedicated to practical, forward-thinking and outcome-focused education; National Psoriasis Foundation and the National Rosacea Society announced as Official Partners
“Dermatology Week is a unique, distraction-free learning experience where the focus will be on dermatology, not destination,” said Dr. Joel Gelfand. MALVERN, Pa. (PRWEB) January 26, 2021 As part of its continued mission to connect the global healthcare community with clinically relevant information and education that improves patient care, the world’s largest healthcare event and education company, HMP Global, today announced the launch of Dermatology Week. The four-day meeting will take place online September 16-19, 2021 and will provide medical and clinical dermatologists, physician assistants, nurse
Mutations in SARS-CoV-2 spike proteolytic cleavage sites may alter transmission dynamics
A study conducted by researchers at the University of Kentucky and the Washington University School of Medicine in the USA has revealed that mutations in the proteolytic cleavage site within the S2 subunit can alter the processing of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, affecting viral entry into host cells. The study’s findings are currently available on the
Background
Since its emergence in December 2019, SARS-CoV-2, the causative pathogen of coronavirus disease 2019 (COVID-19), has already infected over 100 million people and claimed over 2.145 million lives globally. SARS-CoV-2 is known to primarily spread via respiratory droplets, and the interaction between viral spike protein and the host angiotensin-converting enzyme 2 (ACE2) is a prerequisite for viral entry into host cells. Of two distinct subunits of SARS-CoV-2 spike protein, S1 is requi
E-Mail
IMAGE: A new study from Washington University School of Medicine in St. Louis suggests that a two-drug combination targeting a tumor s energy sources could be as effective and less toxic than. view more
Credit: RICHA RATHORE
An innovative approach to treating bone tumors - starving cancer cells of the energy they need to grow - could one day provide an alternative to a commonly used chemotherapy drug without the risk of severe side effects, suggests a new study from Washington University School of Medicine in St. Louis. Studying human cancer cells and mice, the researchers said that a two-drug combination targeting a tumor s energy sources could be as effective and less toxic than methotrexate, a long-used chemotherapy drug often given in high doses to treat osteosarcoma, a bone cancer.
Could aid in assessments of donated kidneys, ID people in early stages of disease
January 22, 2021 SHARE A patient in end-stage kidney disease receives dialysis while he waits for a kidney transplant. Researchers at Washington University School of Medicine in St. Louis have developed an imaging agent that could help refine assessments of kidney health, potentially salvaging some otherwise discarded kidneys. (Photo: Getty Images)
More than 3,000 donated kidneys are discarded every year in the U.S., even as thousands of people die on kidney transplant waitlists. About a fifth of all donated kidneys particularly those from people who are older, have metabolic or cardiovascular conditions, or have died are deemed poor quality. Doctors and patients often refuse such kidneys rather than risk transplanting an organ that might not work.